March 30, 2012
A New Jersey federal judge on Thursday found that four generics makers infringed an AstraZeneca PLC patent on the anti-psychotic Seroquel XR, effectively clearing the path for AstraZeneca to sell the blockbuster drug without generic competition for the next five years.